

Product Name: Solifenacin succinate Revision Date: 01/10/2021

Product Data Sheet

но

Solifenacin succinate

| Cat. No.: | B1614 |
|-----------|----------------------------|
| CAS No.: | 2 <mark>424</mark> 78-38-2 |
| Formula: | C27H32N2O6 |
| M.Wt: | 480.55 |
| Synonyms: | |
| Target: | Neuroscience |
| Pathway: | Muscarinic Receptor |
| Storage: | Store at -20°C |
| | |

Solvent & Solubility

| | ≥24.05 mg/mL in DI | ≥24.05 mg/mL in DMSO; ≥23.6 mg/mL in EtOH with ultrasonic; ≥53.6 mg/mL in H2O | | | |
|--------------------------------------|--------------------|---|-----------|------------|------------|
| Preparing In Vitro Stock Solution | | Mass Solvent Concentration | 1mg | 5mg | 10mg |
| | Slock Solutions | 1 mM | 2.0809 mL | 10.4047 mL | 20.8095 mL |
| | 810 | 5 mM | 0.4162 mL | 2.0809 mL | 4.1619 mL |
| | PERM | 10 mM | 0.2081 mL | 1.0405 mL | 2.0809 mL |

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Muscarinic receptor antagonist

20

IC₅₀ & Target

In Vitro

| Cell Viability Assay | Construction of the second s |
|----------------------|---|
| Cell Line: | Bladder smooth muscle cells, CEM human leukemic T cells |
| Preparation method: | The solubility of this compound in DMSO is >24.1mg/mL. General tips for |
| | obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes |
| | and/or shake it in the ultrasonic bath for a while. Stock solution can be stored |
| | below -20°C for several months. |
| Reacting conditions: | 0.1 nM-1 μM |
| | |

1 | www.apexbt.com

| | Applications: | In bladder smooth muscle cells, solifenacin inhibited Ca2+ mobilization |
|-------------------------------|--|--|
| | | induced by 10 μM carbachol in a concentration-dependent manner. In CEM |
| | | human leukemic T cells, YM905 (10 nM to 10 μ M) significantly reduced the |
| | | number of cells responding to 10 µM Oxo-M. YM905 attenuated the |
| | | upregulation of c-fos mRNA expression induced by 10 μ M Oxo-M, though it has |
| | 210 | no effect on basal expression of c-fos mRNA at 1 or 10 μ M. |
| | Animal experiment | of Classical States |
| | Animal models: | Female Wistar rats, Mice |
| Dosage form: Applications: | Dosage form: | Intravenous injection, 0.03-1 mg/kg |
| | YM905 (0.03-1 mg/kg, i.v.) dose-dependently and significantly suppressed | |
| | increases in intravesical pressure. YM905 (0.1 mg/kg, i.v.) had no effect of | |
| | | salivary secretion. YM905 (i.v.) showed more than about 50% inhibition at 0. |
| | mg/kg. YM905 showed significantly more potent inhibition of bladde | |
| | | responses over salivary responses, with ID30 and ID50 values indicating 6.5 |
| | 610 | and 3.7-fold greater selectivity for urinary bladder, respectively. YM905 potent |
| In Vivo | OF | inhibited restraint stress-induced fecal pellet output in fed rats (ED50: 4. |
| | A Present | mg/kg) and diarrhea in fasted rats (ED50: 1.7 mg/kg). YM905 inhibite |
| | | 5-hydroxytryptamine (5-HT)-, prostaglandin E2- and castor oil-induce |
| | | secretory diarrhea in mice (ED50: 5.5, 14 and 6.3 mg/kg, respectively), but |
| | | showed no significant effect on cholera toxin-induced intestinal secretion i |
| | | mice. YM905 (3, 10 mg/kg) reversed morphine-decreased postprandia |
| | | defecation in ferrets, a model of spastic constipation. |
| | Other notes: | Please test the solubility of all compounds indoor, and the actual solubility ma |
| | 0 | slightly differ with the theoretical value. This is caused by an experimenta |
| | E. P. | system error and it is normal. |
| | | |

See more customer validations on www.apexbt.com.

References

[1]. Ohtake, A., Ukai, M., Hatanaka, T., Kobayashi, S., Ikeda, K., et, al (2004). In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. European journal of pharmacology, 492(2), 243-250.
[2]. Fujii, T., & Kawashima, K. (2000). YM905, a novel M 3 antagonist, inhibits Ca 2+ signaling and c-fos gene expression mediated via

APEBIO

muscarinic receptors in human T cells. General Pharmacology: The Vascular System, 35(2), 71-75.

[3]. Kobayashi, S., Ikeda, K., Suzuki, M., Yamada, T., & Miyata, K. (2001). Effects of YM905, a novel muscarinic M3-receptor

antagonist, on experimental models of bowel dysfunction in vivo. The Japanese journal of pharmacology, 86(3), 281-288.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com 7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com







